Humane Genomics Analysis: $125K Raised
What is Humane Genomics?
Humane Genomics engineers viruses to create precision therapies that target and eliminate cancer cells.
Employees
5
Founded
2019
Revenue
$1.1-1.6M
Investors
- Union Square Ventures
Product Features & Capabilities
- RNA-based viral therapies, selective infection and replication, high lytic activity, >1000 on-target to off-target kill ratio, pediatric liver cancer (hepatoblastoma) treatment, in vivo safety data, 50% reduction in tumor volume.
How much Humane Genomics raised
1 - $125,000
September 1, 2021Lead Investor: Y Combinator
Who are the founders of Humane Genomics
PW
Peter Weijmarshausen
Founder
CM
Chad Moles
Founder
Competitors Overview
Humane Genomics operates in the field of cancer therapies, specifically focusing on engineered viruses to target and destroy cancer cells. Its main competitors include:
- HelixNano: This company is developing next-generation mRNA technologies and cancer vaccines that augment the immune system'
Market Focus
Humane Genomics primarily focuses on the biotechnology industry, specifically in the development of precision therapies that utilize engineered viruses to target and destroy cancer cells.
See something that needs updating? Suggest edits to this profile.